Genkyotex Company

Genkyotex is a biopharmaceutical company that develops innovative drugs to treat acute and chronic diseases by blocking enzymes that produce oxygen radicals. They aim to improve specificity, safety, and efficacy over existing antioxidant therapies and target therapeutic areas such as cardiovascular, metabolic, and neurodegenerative diseases. Genkyotex is the leading company in developing NOX therapies by selectively inhibiting NOX enzymes that amplify multiple disease processes like fibrosis, inflammation, pain processing, cancer development, and neurodegeneration.


Estimated Revenue: €1.6 million
Industry: P4 Medicine
Employee Number: 11-50
Headquarters: Geneva, Geneve
Founded Date: 2006